Published in Hepatitis Weekly, November 27th, 2006
Study 1: A study from India has reported on an association of core promoter mutations with virologic breakthrough (VBTH) breakthrough in chronic hepatitis B (CHB) patients on long-term lamivudine therapy.
"VBTH during long-term lamivudine therapy is believed to be due to the emergence of rtYM204I/VDD mutants. We observed VBTH in 17 of 67 patients receiving long-term lamivudine therapy," wrote S.N. Kazim and colleagues, GB Pant Hospital.
"The YMDD mutant at the onset of VBTH and/or subsequently was seen in eight (47%) of 17 such...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly